Skip to main content
PMC home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1997 Sep-Dec;70(5-6):523–533.

The relevance of somatostatin receptors in thyroid neoplasia.

H Ahlman 1, L E Tisell 1, B Wängberg 1, M Fjälling 1, E Forssell-Aronsson 1, L Kölby 1, O Nilsson 1
PMCID: PMC2589271  PMID: 9825479

Abstract

111In-octreotide scintigraphy in patients with persistent medullary thyroid carcinoma (MTC) visualized tumors in about half of the surgically explored sites. Tumor visualization correlated with rapid tumor growth and large tumor volume as judged from calcitonin levels. The 111In concentration ratio between tumor (T) and blood (B) in surgically excised lymph node metastases of MTC showed a large variation, with low values for microscopic and high values for macroscopic metastases in individual patients. Three cases of MTC, Hürthle cell adenoma and papillary thyroid cancer are reported with preoperative scintigraphy, T/B ratios and Northern analyses of the surgical biopsies. Visualization of tumors was possible in the absence of sstr2 (the high affinity receptor for octreotide) with the exception of microscopic tumor growth. T/B values in the patient with Hürthle cell adenoma were similar to those found in the contralateral thyroid lobe with goitre. The relatively high uptake of 111In in benign thyroid conditions probably limits the use of octreotide scintigraphy in the diagnosis of primary tumors. The technique has certain advantages over radioiodine scintigraphy after the surgical treatment of thyroid tumors: no need for withdrawal of thyroxin substitution; a possibility to diagnose metastases of tumors that do not concentrate radioiodine (MTC, Hürthle cell cancer); and complementary information about metastatic sites of non-medullary thyroid cancer (papillary and follicular tumors).

Full text

PDF
523

Images in this article

526Figure 1
on p.526
528Figure 2
on p.528
529Figure 3
on p.529
530Figure 4
on p.530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlman H., Wängberg B., Tisell L. E., Nilsson O., Fjälling M., Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg. 1994 Aug;81(8):1144–1149. doi: 10.1002/bjs.1800810820. [DOI] [PubMed] [Google Scholar]
  2. Baudin E., Lumbroso J., Schlumberger M., Leclere J., Giammarile F., Gardet P., Roche A., Travagli J. P., Parmentier C. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996 Jun;37(6):912–916. [PubMed] [Google Scholar]
  3. Becker W., Schrell U., Buchfelder M., Hensen J., Wendler J., Gramatzki M., Wolf F. Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy. Nuklearmedizin. 1995 Jun;34(3):100–103. [PubMed] [Google Scholar]
  4. Bergholm U., Adami H. O., Bergström R., Bäckdahl M., Akerström G. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chir Scand. 1990 Jan;156(1):37–46. [PubMed] [Google Scholar]
  5. Bruns C., Weckbecker G., Raulf F., Kaupmann K., Schoeffter P., Hoyer D., Lübbert H. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994 Sep 15;733:138–146. doi: 10.1111/j.1749-6632.1994.tb17263.x. [DOI] [PubMed] [Google Scholar]
  6. Buhr H. J., Lehnert T., Raue F. New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid. Eur J Surg Oncol. 1990 Aug;16(4):366–369. [PubMed] [Google Scholar]
  7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  8. Forssell-Aronsson E., Fjälling M., Nilsson O., Tisell L. E., Wängberg B., Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl Med. 1995 Jan;36(1):7–12. [PubMed] [Google Scholar]
  9. Frank-Raue K., Bihl H., Dörr U., Buhr H., Ziegler R., Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995 Jan;42(1):31–37. doi: 10.1111/j.1365-2265.1995.tb02595.x. [DOI] [PubMed] [Google Scholar]
  10. Gundry S. R., Burney R. E., Thompson N. W., Lloyd R. Total thyroidectomy for Hürthle cell neoplasm of the thyroid. Arch Surg. 1983 May;118(5):529–532. doi: 10.1001/archsurg.1983.01390050013002. [DOI] [PubMed] [Google Scholar]
  11. Kwekkeboom D. J., Reubi J. C., Lamberts S. W., Bruining H. A., Mulder A. H., Oei H. Y., Krenning E. P. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993 Jun;76(6):1413–1417. doi: 10.1210/jcem.76.6.8501144. [DOI] [PubMed] [Google Scholar]
  12. Maxon H. R., 3rd, Smith H. S. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990 Sep;19(3):685–718. [PubMed] [Google Scholar]
  13. Miyauchi A., Onishi T., Morimoto S., Takai S., Matsuzuka F., Kuma K., Maeda M., Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984 Apr;199(4):461–466. doi: 10.1097/00000658-198404000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Postema P. T., De Herder W. W., Reubi J. C., Oei H. Y., Kwekkeboom D. J., Bruining H. J., Bonjer J., van Toor H., Hennemann G., Krenning E. P. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion. 1996;57 (Suppl 1):36–37. doi: 10.1159/000201391. [DOI] [PubMed] [Google Scholar]
  15. Rohrer L., Raulf F., Bruns C., Buettner R., Hofstaedter F., Schüle R. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci U S A. 1993 May 1;90(9):4196–4200. doi: 10.1073/pnas.90.9.4196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tisell L. E., Ahlman H., Wängberg B., Hansson G., Mölne J., Nilsson O., Lindstedt G., Fjälling M., Forssell-Aronsson E. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg. 1997 Apr;84(4):543–547. [PubMed] [Google Scholar]
  17. Tisell L. E., Dilley W. G., Wells S. A., Jr Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery. 1996 Jan;119(1):34–39. doi: 10.1016/s0039-6060(96)80210-8. [DOI] [PubMed] [Google Scholar]
  18. Tisell L. E., Hansson G., Jansson S., Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986 Jan;99(1):60–66. [PubMed] [Google Scholar]
  19. Tsuzaki S., Moses A. C. Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells. Endocrinology. 1990 Jun;126(6):3131–3138. doi: 10.1210/endo-126-6-3131. [DOI] [PubMed] [Google Scholar]
  20. Vattimo A., Bertelli P., Cintorino M., Burroni L., Volterrani D., Vella A. Identification of Hürthle cell tumor by single-injection, double-phase scintigraphy with technetium-99m-sestamibi. J Nucl Med. 1995 May;36(5):778–782. [PubMed] [Google Scholar]
  21. Wangberg B., Forssell-Aronsson E., Tisell L. E., Nilsson O., Fjalling M., Ahlman H. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Br J Cancer. 1996 Mar;73(6):770–775. doi: 10.1038/bjc.1996.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wells S. A., Jr, Baylin S. B., Gann D. S., Farrell R. E., Dilley W. G., Preissig S. H., Linehan W. M., Cooper C. W. Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Ann Surg. 1978 Sep;188(3):377–383. doi: 10.1097/00000658-197809000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Williams L. E., Duda R. B., Proffitt R. T., Beatty B. G., Beatty J. D., Wong J. Y., Shively J. E., Paxton R. J. Tumor uptake as a function of tumor mass: a mathematic model. J Nucl Med. 1988 Jan;29(1):103–109. [PubMed] [Google Scholar]
  24. Yamada Y., Kagimoto S., Kubota A., Yasuda K., Masuda K., Someya Y., Ihara Y., Li Q., Imura H., Seino S. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun. 1993 Sep 15;195(2):844–852. doi: 10.1006/bbrc.1993.2122. [DOI] [PubMed] [Google Scholar]
  25. Yamada Y., Reisine T., Law S. F., Ihara Y., Kubota A., Kagimoto S., Seino M., Seino Y., Bell G. I., Seino S. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol. 1992 Dec;6(12):2136–2142. doi: 10.1210/mend.6.12.1337145. [DOI] [PubMed] [Google Scholar]
  26. degli Uberti E. C., Hanau S., Rossi R., Piva R., Margutti A., Trasforini G., Pansini G., del Senno L. Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro. J Clin Endocrinol Metab. 1991 Jun;72(6):1364–1371. doi: 10.1210/jcem-72-6-1364. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES